IsraelHealthcare and life sciences2024 – ongoingNano-X Imaging
AI findings added to the Second Opinions teleradiology platform
Nano-X added three FDA-cleared AI tools to its Second Opinions service, with physicians approving every finding
Problem
Patients who send chest or abdominal CT scans to a teleradiology second-opinion service may have signs of chronic disease that the original scan was not read for.
Approach
Nanox AI, Nano-X's deep-learning subsidiary, integrated three FDA 510(k)-cleared tools into Second Opinions, a platform run by USARAD Holdings. The tools measure coronary artery calcium, bone mineral density with vertebral compression fractures, and liver density as a marker of fatty liver. Physicians review and approve the AI findings before they go into the patient report.
Results
No published figures
Takeaway
Nano-X kept a physician sign-off between the algorithm and the report. The release gave no accuracy or volume figures.
Categories
- Industry
- Healthcare and life sciences
- Business function
- Production and quality
- Innovation type
- Product and service innovation
- AI technology
- Computer visionPredictive analytics and ML
- Adoption
- Built in-house
- Goal
- Quality and risk
- Evidence
- Company's own claim
Sources
Source summaries
Nano-X's release says AI for cardiac calcium, bone density and liver density now runs on chest and abdominal CT scans in Second Opinions. Physicians review and approve findings before they enter patient reports. It gives no accuracy, volume or financial figures.
Full details are in the original sources.
